Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial. - Wikidata - awgldk - TriplyDB

Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.

Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.

http://www.wikidata.org/entity/Q37384560

about

Denosumab and surgery for the treatment of Perthes' disease in a 9-year-old boy: favorable course documented by comprehensive imaging- a case report.Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Denosumab: an Emerging Therapy in Pediatric Bone Disorders.Developments in rare bone diseases and mineral disorders.Splenomegaly, myeloid lineage expansion and increased osteoclastogenesis in osteogenesis imperfecta murine.Osteogenesis imperfecta and therapeutics.Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease.Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI.

P2860

Q33697123-CF39CFEC-BE87-4C43-8610-3FD7168AE33A Q34545263-6D38AA51-AC93-44A3-B965-346CF10FA646 Q38712724-CE285293-E1DF-4BCD-A2AC-331FAFC82788 Q49413973-1B0A76C2-A1AD-4AFD-AEBB-72A94ECF2A02 Q51816827-C20436F5-6D86-4B05-B8CF-F1567936C960 Q52655586-2671595A-579B-4A92-93CA-EE99DC129455 Q52729477-27684B45-F67C-4AFA-B50E-E0047FAA5B67 Q54990084-555695B7-AC09-4521-8DCC-AE215BC7A1B9

P2860

Safety and efficacy of denosumab in children with osteogenesis imperfect--a first prospective trial.

http://www.wikidata.org/entity/Q37384560

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on March 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Safety and efficacy of denosum ...... ct--a first prospective trial.

@en

Safety and efficacy of denosum ...... ct--a first prospective trial.

@nl

type

label

Safety and efficacy of denosum ...... ct--a first prospective trial.

@en

Safety and efficacy of denosum ...... ct--a first prospective trial.

@nl

prefLabel

Safety and efficacy of denosum ...... ct--a first prospective trial.

@en

Safety and efficacy of denosum ...... ct--a first prospective trial.

@nl

P1433

Q37384560-6EE56A72-F333-473C-857F-AC5F31B9ADD9

P1476

Q37384560-1846FE60-7679-458F-9186-5393433B8816

P2093

Q37384560-0B978F30-1BE1-4237-8BE2-1B4B1B2B75EA

Q37384560-157CE843-B829-4079-9FCD-0CF0584F62FE

Q37384560-1D3F0D91-72DA-4725-A823-78A0FEB40DAD

Q37384560-27167432-34D8-4AA2-8B6D-2B63B703A35B

Q37384560-496744D9-415E-4F0E-91E5-9773AE72AB95

Q37384560-54792555-C4B3-4546-AC4A-361B2C9BB94E

Q37384560-6C287593-7E4F-4B94-B929-D1BA3BD1D609

Q37384560-E8BC8AC9-C232-4713-80D9-4C95AC349E7E

Q37384560-F9B6CB68-FA61-4C25-9717-F18B83F18EC4

P2860

Q37384560-03B3CB51-B073-4AFD-B24E-4AB806D4E847

Q37384560-08285378-FA8E-4FB4-AC67-ADAA1A5E3689

Q37384560-0DBE315D-CEDC-471D-943B-4313E1CCD7F1

Q37384560-11451515-D832-4817-A728-FE11969C9731

Q37384560-1FF882E1-97BE-4B2F-BEB3-E3FCC964E99D

Q37384560-26BFBF1C-271F-424A-8EB3-75EA65F04740

Q37384560-283B16A2-85DA-4EBA-A3D4-2BF0AAD95877

Q37384560-297CDF04-231C-44A8-8B4F-64F8EDE8DFFD

Q37384560-3070E2A9-CFDF-449B-9AD4-1F76401BEBBB

Q37384560-36114DBC-9B68-4846-9A91-CF0916A0D5B5

P304

Q37384560-D047F187-9E4E-46DD-93E8-C0F87A576A3B

P31

Q37384560-F81C7EA4-1C41-4B86-BC6D-F7AC16ECD3AF

P433

Q37384560-C177120D-EA9B-489B-966B-96946BAA9024

P478

Q37384560-F22852CA-90C3-4EA7-8ED8-5E9E16F8B000

P577

Q37384560-3D9DA8AE-B2AC-49AD-8F5D-BC5A3C8FF86E

P698

Q37384560-424D1B2F-7356-440F-A04B-65F37F9818AE

P932

Q37384560-807A1423-2FE0-486A-85E0-50D17A62AD42

P1433

The Journal of Musculoskeletal and Neuronal Interactions

P1476

Safety and efficacy of denosum ...... ct--a first prospective trial.

@en

P2093

B Hero

http://www.w3.org/2001/XMLSchema#string

C Netzer

http://www.w3.org/2001/XMLSchema#string

E Schoenau

http://www.w3.org/2001/XMLSchema#string

G Allo

http://www.w3.org/2001/XMLSchema#string

H Hoyer-Kuhn

http://www.w3.org/2001/XMLSchema#string

J Franklin

http://www.w3.org/2001/XMLSchema#string

M Kron

http://www.w3.org/2001/XMLSchema#string

O Semler

http://www.w3.org/2001/XMLSchema#string

P Eysel

http://www.w3.org/2001/XMLSchema#string

P2860

Bisphosphonate therapy for osteogenesis imperfecta

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation

Denosumab in postmenopausal women with low bone mineral density

National Health and Nutrition Examination Survey whole-body dual-energy X-ray absorptiometry reference data for GE Lunar systems.

Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.

Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study.

Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.

Two years' experience with denosumab for children with osteogenesis imperfecta type VI

Osteogenesis imperfecta.

P304

24-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26944820

http://www.w3.org/2001/XMLSchema#string

P932

5089451

http://www.w3.org/2001/XMLSchema#string